Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.

ABSTRACT:

Introduction

Recombinant acellular pertussis (ap) vaccines containing genetically inactivated pertussis toxin (PT_gen) and filamentous hemagglutinin (FHA) with or without tetanus (TT) and diphtheria (DT) vaccines (Td) were found safe and immunogenic in non-pregnant and pregnant women. We report here maternal antibody transfer and safety data in mothers and neonates.

Methods

This is the follow up of a phase 2 trial in 2019 among 400 pregnant women who randomly received one dose of recombinant pertussis-only vaccine containing 1 µg PT_gen and 1 µg FHA (ap1_gen), or Td combined with ap1_gen (Tdap1_gen), or with 2 µg PT_gen and 5 µg FHA (Tdap2_gen), or with 5 µg PT_gen and 5 µg FHA (TdaP5_gen,

SUBMITTER: Chokephaibulkit K 

PROVIDER: S-EPMC10789266 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature